BOZEN, Sud-Tirol, Italy, May 30, 2013 /PRNewswire/ --
Health Robotics today released to the pharmacy community its official answers to the ASHP's IV Robotics Vendor Survey, in conjunction with its pre-planned activities around ASHP's Summer Meeting and Exhibition (Booth 425), to be held June 1 through June 5 at the Minneapolis Convention Center [MN].
Several Health Robotics' prospective customers submitted to the company during the last few months copies of the ASHP's recommended IV Robotics Vendor Survey, seeking from Health Robotics' its answers to ASHP's recommendations. While Health Robotics answered prospective customers individually, it now decided to post its official answers for the rest of the pharmacy community to consider. http://www.health-robotics.com/en/compare-products/ASHP-IVRoboticsSurvey.pdf
Gaspar DeViedma, Health Robotics' Executive Vice President stated: "I look forward to ASHP's Summer Meeting and Exhibition this week, and to personally thank the North American pharmacy community for their confidence in making Health Robotics the undisputed leader in its industry only 2 years after it began operations in the USA. With more than 100 North American installations currently under contract, I expect that number to reach 200 installations by the end of 2013, which would have not been possible without the leadership of our key customers."
About Health Robotics:
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing almost 400 hospital installations in 5 continents with the only fully-integrated Robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies,] to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput, and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
For additional information, please contact:
SOURCE Health Robotics